
## CLAIMS

1. A compound of Formula I or a pharmaceutically acceptable salt thereof:



I ,

wherein R is H or $C_{1-5}$ alkyl, and the $C_{1-5}$ alkyl is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, neo-butyl, n-pentyl, isopentyl, neo-pentyl, cyclopentyl, or $C_{1-5}$ alkyl substituted by halogen, hydroxy, carboxyl, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{3-8}$ cycloalkyl, $C_{3-8}$ heterocyclyl, $C_{3-8}$ cycloalkoxy, aryl, and heteroaryl; the number of R is 0, 1, 2, 3 or 4;

$Ar_1$ is selected from the group consisting of diphenyl ether, benzofuryl, benzimidazolyl, benzoxazolyl, benzothiophenyl, quinolyl, isoquinolyl and purinyl;

$Ar_2$ are $C_{5-18}$ aryl;

$X_1$ and $X_2$ are respectively and independently one or more substituents selected from the group consisting of H, hydroxy, carboxyl, halogen, acyloxy, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{3-8}$ cycloalkyl, $C_{3-8}$ heterocyclyl, $C_{3-8}$ cycloalkoxy, aryl, heteroaryl, and $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{3-8}$ cycloalkyl, $C_{3-8}$ heterocyclyl, $C_{3-8}$ cycloalkoxy, aryl, and heteroaryl that are substituted by hydroxy, carboxyl, halogen and alkyl, at any substitution position.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the $X_1$ and the $X_2$ are respectively and independently one or more substituents selected from the group consisting of H, hydroxy, carboxyl, halogen, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{3-8}$ cycloalkyl, $C_{3-8}$ heterocyclyl, $C_{3-8}$ cycloalkoxy, aryl, heteroaryl, and $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{3-8}$ cycloalkyl, $C_{3-8}$ heterocyclyl, $C_{3-8}$ cycloalkoxy, aryl, and heteroaryl that are substituted by hydroxy, carboxyl, halogen and alkyl, at any substitution position.

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the $X_1$ and the $X_2$ are respectively and independently one or more substituents selected from the group consisting of H, hydroxy, halogen, acyloxy, $C_{1-3}$ alkyl, and $C_{1-3}$ alkoxy, at any substitution position.

4. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the $Ar_1$ is one or more substituents selected from the group consisting of diphenyl ether, indolyl and biphenyl, at any substitution position.

5. The compound of Formula I or a pharmaceutically acceptable salt thereof according to claim 1, wherein if the R is H.

6. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the $X_1$ and the $X_2$ are respectively and independently one or more substituents selected from the group consisting of H, hydroxy, halogen, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{3-8}$ heterocyclyl, $C_{3-8}$ cycloalkoxy, and $C_{1-3}$ alkyl and $C_{1-3}$ alkoxy that are substituted by hydroxy, halogen and alkyl, at any substitution position.

7. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein,

the $Ar_1$ is diphenyl ether or biphenyl, at any substitution position;

the $X_1$ is one or more of H, methoxy, hydroxy, F and Cl, at any substitution position;

the $Ar_2$ is phenyl, at any substitution position; and

the $X_2$ is one or more of H, methyl, dimethyl, methoxy, hydroxy, F and Cl, at any substitution position.

8. The compound or a pharmaceutically acceptable salt thereof according to claim 5, wherein the $Ar_1$ has a substitution position of meta-position.

9. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein,


the $Ar_1$ is benzofuryl, benzimidazolyl, benzoxazolyl, benzothiophenyl, indolyl, quinolyl, isoquinolyl or purinyl, at any substitution position;

the $X_1$ is one or more substituents selected from the group consisting of H, methyl, methoxy, hydroxy, F, Cl and Br, at any substitution position;


the $Ar_2$ is phenyl, at any substitution position;

the $X_2$ is one or more substituents selected from the group consisting of H, methyl, dimethyl, methoxy, hydroxy, F and Cl, at any substitution position.


10. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:




MAGLZ-II-01




MAGLZ-II-02




MAGLZ-II-03




MAGLZ-II-04




MAGLZ-II-06




MAGLZ-II-08




MAGLZ-II-09




MAGLZ-II-10




MAGLZ-II-11




MAGLZ-II-12




MAGLZ-II-13




MAGLZ-II-15




MAGLZ-II-16




MAGLZ-II-17




MAGLZ-II-20




MAGLZ-II-22




MAGLZ-II-23




MAGLZ-II-24




MAGLZ-II-25




MAGLZ-II-26




MAGLZ-II-27




MAGLZ-II-29




MAGLZ-II-18(a)




MAGLZ-II-18(c)




MAGLZ-II-30



MAGLZ-II-31




MAGLZ-II-11(a)




MAGLZ-II-11F


and



MAGLZ-II-11J


.


11. A compound of Formula III  or a pharmaceutically acceptable salt thereof, wherein the $R_1$ is selected from hydroxy, F, Cl, Br, I, methyl, ethyl, propyl, and methoxy; the $R_2$ is selected from I, ethyl, and propyl, ; the number of the $R_1$ and the $R_2$ is 0, 1, 2, 3, or 4; the link mode between the $R_1$, the $R_2$ and nucleus is not limited to a single connection via a single bond.


12. A method of synthesizing the compound of Formula I, comprising the following specific steps: 



b

I

, wherein b or a salt of b is reacted with  to obtain I; the $X_1$, the $X_2$, the $Ar_1$ and the $Ar_2$ are as described in claim 1.

13. The synthesizing method according to claim 12, wherein the b or the salt of b is reacted with  to obtain I; a condensating agent and an alkali are added in this step to facilitate the reaction; wherein, the condensating agent is selected from HBTU, DMC, HOBT, HOBT/EDCI, HATU, HATU/DIEPA, DCC, CDI, and isopropyl chloroformate.

14. The synthesizing method according to claim 12, wherein the b or the salt of b is obtained by deprotection of a; 
a b .


15. The synthesizing method according to claim 12, wherein the a or the salt of a is obtained by reacting sm with  or a salt thereof; 
sm a .

16. A pharmaceutical composition, comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-11, and a pharmaceutically acceptable carrier.


17. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-11 in the preparation of a medicament for treating a MAGL-mediated disease or condition, wherein the MAGL-mediated disease or condition is selected from the group consisting of: metabolic disorders, nephrosis, emesis or vomiting or nausea, eating disorders, neuropathy, schizophrenia, depressive disorders, bipolar disorders, fremitus, dyskinesia, abstinence syndromes, traumatic brain injury, non-traumatic brain injury, spinal cord injury, epileptic seizure, conditions associated with abnormal cell growth or proliferation [such as, benign tumors or cancers], inflammatory conditions, immune system conditions, irritable bowel syndromes, ulcer colonitis, acute stress disorders, substance-inducing anxiety,

obsessive-compulsive disorders, anxiety disorders; attention deficiency disorders, attention deficit hyperactivity disorders, pains, migraine, demyelinating diseases, and cognitive impairments.


18. Use of a compound or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a MAGL-mediated disease or condition, wherein the compound is selected from the group consisting of:




MAGLZ-II-05




MAGLZ-II-07




MAGLZ-II-14



MAGLZ-II-18



MAGLZ-II-19



MAGLZ-II-21

, and

the MAGL-mediated disease or condition is selected from the group consisting of: metabolic disorders, nephrosis, emesis or vomiting or nausea, eating disorders, neuropathy, schizophrenia, depressive disorders, bipolar disorders, fremitus, dyskinesia, abstinence syndromes, traumatic brain injury, non-traumatic brain injury, spinal cord injury, epileptic seizure, conditions associated with abnormal cell growth or proliferation [such as, benign tumors or cancers], inflammatory conditions, immune system conditions, irritable bowel syndromes, ulcer colonitis, acute stress disorders, substance-inducing anxiety, obsessive-compulsive disorders, anxiety disorders; attention deficiency disorders, attention deficit hyperactivity disorders, pains, migraine, demyelinating diseases, and cognitive impairments.